Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza

The firm is currently evaluating Byetta, Victoza and Januvia lawsuits for those who have suffered from the allegedly serious side effects of the drugs.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
The Rottenstein Law Group LLP maintains Byetta, Januvia and Victoza lawsuit pages on its website.

The Rottenstein Law Group LLP maintains Byetta, Januvia and Victoza lawsuit pages on its website.

For the plaintiffs in Byetta, Januvia and Victoza lawsuits, the results of the review could serve as valuable supporting evidence for their cases.

(PRWEB) June 13, 2013

Following the American Diabetes Association’s call for a safety review of diabetes drugs because of potential pancreatic cancer links, the makers of Byetta, Januvia and Victoza announced June 12 they will voluntarily participate in the new evaluation of clinical data, according to Reuters.* The Rottenstein Law Group LLP, which maintains Byetta, Januvia and Victoza lawsuit pages on its website and represents clients in cases involving all three drugs, offers its assessment of the impact on type 2 diabetes drug lawsuits.

The news comes after a March 2013 announcement** by the U.S. Food and Drug Administration that it was studying reports that the drugs caused inflammation of the pancreas and pre-cancerous changes to the cells of the pancreas, according to Reuters. Bristol-Myers Squibb makes Byetta, Merck Januvia and Novo Nordisk Victoza.

“There is increasing evidence of a connection between pancreatic cancer risks and these diabetes drugs,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “For the plaintiffs in Byetta, Januvia and Victoza lawsuits, the results of the review could serve as valuable supporting evidence for their cases.”

The Rottenstein Law Group LLP’s website features dedicated pages for each of the three drugs that each offer informational brochures that discuss the steps that need to be taken by those who believe their diabetes drug has injured them.

*reuters.com/article/2013/06/12/us-diabetes-safety-idUSBRE95B17J20130612?feedType=RSS&feedName=healthNews (June 12, 2013)

**fda.gov/Drugs/DrugSafety/ucm343187.htm

For the latest news on defective medications and medical devices and related lawsuits, visit the Rottenstein Law Group LLP’s Injury Lawyer Newswire at injurylawyernewswire.com. Readers can subscribe to the news site’s stories and videos to stay on top of personal injury news.

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com

###